The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Diaclide MR 60 mg modified-release tablets

McDermott Laboratories Ltd., T/A Gerard LaboratoriesPA0577/030/003

Main Information

Trade NameDiaclide MR 60 mg modified-release tablets
Active SubstancesGliclazide
Dosage FormModified-release tablet
Licence HolderMcDermott Laboratories Ltd., T/A Gerard Laboratories
Licence NumberPA0577/030/003

Group Information

ATC CodeA10BB Sulfonamides, urea derivatives
A10BB09 gliclazide


License statusAuthorised
Licence Issued13/02/2015
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0086-127-050
Interchangeable List DocumentPDF of Interchangeable List
« Back